News

Floorstocks Releases Exclusive Nasdaq MarketSite Interview with Wellgistics Health Inc. (NASDAQ: WGRX)

  • NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Floorstocks, a financial media platform with over 1.2 million active retail investors, has released an exclusive CEO interview filmed at the Nasdaq MarketSite with Brian Norton, CEO of Wellgistics Health Inc. (NASDAQ: WGRX). The full interview is now available on YouTube and Floorstocks.com, offering investors a front-row look at one of healthcare's most disruptive emerging growth companies.
    07/10/2025

Wellgistics Health (NASDAQ:WGRX) Accelerates Platform Growth in Q2 With 116 Manufacturer Partnerships, 12,400+ New Products, and 275+ Pharmacies Added to Its Expanding Tech Based Drug Ecosystem

  • TAMPA, FL / ACCESS Newswire / June 25, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare technology company focused on building the future of prescription access and distribution, today announced significant Q2 2025 operational results-adding 116 new pharmaceutical manufacturer partnerships, over 12,400 new products (NDCs), and 275+ pharmacies to its national platform. This expansion reflects Wellgistics' accelerating momentum in creating a modern drug ecosystem-one that aims to connect manufacturers directly to pharmacies, providers, employers, and patients through a fully integrated, AI-powered infrastructure designed to streamline fulfillment, reduce costs, and bypass legacy bottlenecks.
    06/25/2025
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Wellgistics Health, Inc. (WGRX) can sell. Click on Rating Page for detail.

The price of Wellgistics Health, Inc. (WGRX) is 1.01 and it was updated on 2025-07-19 07:00:37.

Currently Wellgistics Health, Inc. (WGRX) is in undervalued.

News
    
News

Wellgistics Health Joins OptiSource to Expand Access and Drive Savings for Independent Pharmacies

  • TAMPA, FL / ACCESS Newswire / June 10, 2025 / Wellgistics Health (NASDAQ:WGRX) ("Wellgistics Health"), a next-generation drug distribution, digital script routing, and hub fulfillment platform, is proud to announce its official membership in OptiSource, LLC, a group purchasing organization that provides innovative business solutions, group purchasing programs, and other efficiency-enhancing and cost-saving services to its members. This strategic move significantly enhances Wellgistics Health's purchasing power, product access, and support for community-based pharmacy partners.
    Tue, Jun. 10, 2025

Wellgistics Health Announces Preliminary Inclusion in the Russell 2000 and Russell 3000 Indexes

  • TAMPA, FLORIDA / ACCESS Newswire / May 29, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced its preliminary inclusion in the Russell 2000 and Russell 3000 Indexes, as part of the 2025 Russell US Indexes annual reconstitution. FTSE Russell released the preliminary list of additions and deletions to the Russell 2000 and Russell 3000 Indexes on Friday, May 23, with final inclusion expected to take effect following the close of the U.S. equity market on Friday, June 27, 2025.
    Thu, May. 29, 2025

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

  • TAMPA, FLORIDA / ACCESS Newswire / May 28, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a healthcare infrastructure company transforming the prescription drug ecosystem, today announced key additions to its executive leadership team and Board of Directors. These strategic appointments reflect the Company's commitment to executing on its growth strategy, enhancing operational scale, and delivering long-term shareholder value.
    Wed, May. 28, 2025

Wellgistics Health Reports 36% Revenue Growth in Q1 2025 as Manufacturer Access and Pharmacy Onboarding Accelerate

  • TAMPA, FL / ACCESS Newswire / May 12, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX, "Wellgistics Health"), a healthcare infrastructure and pharmaceutical distribution company leveraging proprietary technology, today announced financial results for its first fiscal quarter ended March 31, 2025. Revenue for the Q1 2025 quarter increased to $10.86 million from zero during the comparable period last year on a GAAP basis.
    Mon, May. 12, 2025

CORRECTION FROM SOURCE: Wellgistics Health Secures $50M ELOC Facility for XRP Treasury Reserve and Real-Time Payments Infrastructure and Other General Ops

  • The correction is to the headline only TAMPA, FL / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
    Thu, May. 08, 2025
SEC Filings
SEC Filings

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 07/08/2025

Wellgistics Health, Inc. (WGRX) - 4

  • SEC Filings
  • 07/08/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 07/08/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 05/15/2025

Wellgistics Health, Inc. (WGRX) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/12/2025

Wellgistics Health, Inc. (WGRX) - EFFECT

  • SEC Filings
  • 05/07/2025

Wellgistics Health, Inc. (WGRX) - 424B3

  • SEC Filings
  • 05/07/2025

Wellgistics Health, Inc. (WGRX) - S-1

  • SEC Filings
  • 05/05/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 04/24/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 04/24/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 04/23/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 04/18/2025

Wellgistics Health, Inc. (WGRX) - DRS

  • SEC Filings
  • 04/15/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 04/11/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 03/27/2025

Wellgistics Health, Inc. (WGRX) - 4

  • SEC Filings
  • 03/25/2025

Wellgistics Health, Inc. (WGRX) - 10-K - Current report

  • SEC Filings
  • 03/25/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 03/21/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 03/21/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 03/14/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 03/12/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 03/06/2025

Wellgistics Health, Inc. (WGRX) - 424B3

  • SEC Filings
  • 03/06/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 02/28/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 02/28/2025

Wellgistics Health, Inc. (WGRX) - 8-K - Current report

  • SEC Filings
  • 02/26/2025

Wellgistics Health, Inc. (WGRX) - 3

  • SEC Filings
  • 02/24/2025

Wellgistics Health, Inc. (WGRX) - 424B4

  • SEC Filings
  • 02/21/2025

Wellgistics Health, Inc. (WGRX) - CERT

  • SEC Filings
  • 02/20/2025

Wellgistics Health, Inc. (WGRX) - 8-A12B

  • SEC Filings
  • 02/18/2025

Wellgistics Health, Inc. (WGRX) - EFFECT

  • SEC Filings
  • 02/14/2025

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 02/14/2025

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 01/14/2025

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 12/18/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 12/17/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 12/16/2024

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 12/06/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 12/06/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 11/13/2024

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 11/06/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 11/05/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 11/04/2024

Wellgistics Health, Inc. (WGRX) - FWP

  • SEC Filings
  • 10/30/2024

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 10/21/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 10/18/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 10/15/2024

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 09/27/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 09/27/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 08/29/2024

Wellgistics Health, Inc. (WGRX) - S-1/A

  • SEC Filings
  • 08/02/2024

Wellgistics Health, Inc. (WGRX) - CORRESP

  • SEC Filings
  • 08/02/2024

Wellgistics Health, Inc. (WGRX) - UPLOAD

  • SEC Filings
  • 08/01/2024

Wellgistics Health, Inc. (WGRX) - S-1

  • SEC Filings
  • 07/22/2024
Press Releases
StockPrice Release

Floorstocks releases exclusive nasdaq marketsite interview with wellgistics health inc. (nasdaq: wgrx)

  • 07/10/2025

Wellgistics health (nasdaq:wgrx) accelerates platform growth in q2 with 116 manufacturer partnerships, 12,400+ new products, and 275+ pharmacies added to its expanding tech based drug ecosystem

  • 06/25/2025

Wellgistics health joins optisource to expand access and drive savings for independent pharmacies

  • 06/10/2025

Wellgistics health announces preliminary inclusion in the russell 2000 and russell 3000 indexes

  • 05/29/2025

Wellgistics health strengthens executive team and board with strategic appointments to accelerate scale and drive shareholder value

  • 05/28/2025

Wellgistics health reports 36% revenue growth in q1 2025 as manufacturer access and pharmacy onboarding accelerate

  • 05/12/2025

Correction from source: wellgistics health secures $50m eloc facility for xrp treasury reserve and real-time payments infrastructure and other general ops

  • 05/08/2025

Wellgistics health secures $50m credit facility and launches xrp-powered payment initiative

  • 05/08/2025

Wellgistics health reports strong q1 operational growth across manufacturer, product, and pharmacy expansion with over 350 new pharmacies added to its nationwide network

  • 04/30/2025

Wellgistics names mark disiena as new cfo

  • 04/24/2025

Ceo of wellgistics health converts $1.5 million of debt to equity at ipo price

  • 04/15/2025

Wellgistics health, inc. announces agreement to acquire peek healthcare technologies, inc., to support over 2,500 patients and $1.5mm annual revenue

  • 04/10/2025

Wellgistics health achieves soc 2 type 1 compliance, strengthening security for ai-driven pharmacy solutions and employer-based healthcare models

  • 03/18/2025

Wellgistics health, inc. announces leadership transition: brian norton appointed as ceo following tim canning's departure

  • 03/04/2025

Protega pharmaceuticals collaborates with wellgistics to support pharmacist education and increase patient access to the first and only fda-approved abuse-deterrent immediate-release opioid, roxybond™

  • 03/04/2025

Wellgistics expands healthcare ecosystem with tollo health agreement, targeting multi-billion dollar glp-1 and long covid market

  • 02/26/2025

Wellgistics health, inc. announces closing of $4.0 million initial public offering

  • 02/24/2025
More Headlines
News

Wellgistics Health Secures $50M Credit Facility and Launches XRP-Powered Payment Initiative

  • TAMPA, FLORIDA / ACCESS Newswire / May 8, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based digital asset, as both a treasury reserve and a real-time payments infrastructure-which management believes, upon successful commercialization, would make Wellgistics among the first publicly traded healthcare companies to deploy XRP in this manner. This XRP payment initiative is supported by Wellgistics Health's $50 million Equity Line of Credit (ELOC), the proceeds of which may be utilized to further develop and unlock programmable liquidity and on-demand financial infrastructure designed to eliminate banking delays, reduce cost, and increase transparency across its national healthcare network.
  • 05/08/2025

Wellgistics Health Reports Strong Q1 Operational Growth Across Manufacturer, Product, and Pharmacy Expansion with Over 350 New Pharmacies Added to Its Nationwide Network

  • TAMPA, FL / ACCESS Newswire / April 30, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced key unaudited operational performance highlights for the first quarter of 2025, signaling continued acceleration across its national platform. Some of Wellgistics Health's Q1 2025 operational highlights include: 354 new independent pharmacies added 22 new pharmaceutical manufacturers onboarded 57 new prescription drug products integrated into the portfolio "These numbers are a clear signal the industry is demanding change," said Brian Norton, CEO of Wellgistics Health.
  • 04/30/2025

Wellgistics Names Mark DiSiena as New CFO

  • TAMPA, FL / ACCESS Newswire / April 24, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced a key leadership change to propel Wellgistics Health's strategic growth initiatives forward by appointing Mark DiSiena as its new Chief Financial Officer. As the new Chief Financial Officer of Wellgistics, Mr.
  • 04/24/2025

CEO of Wellgistics Health Converts $1.5 Million of Debt to Equity at IPO Price

  • TAMPA, FL / ACCESS Newswire / April 15, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that it has entered into an amendment to the Membership Interest Purchase Agreement with Wellgistics LLC and Wellgistics LLC's former owners to convert a significant cash payment owed by the Company into shares of the Company's common stock at the initial public offering price of $4.50 per share. Specifically, the Company has converted $1.5 million in debt that the Company owed to a seller entity controlled by Brian Norton, its Chief Executive Officer, and that the Company would have needed to pay by June 14, 2025.
  • 04/15/2025

Wellgistics Health, Inc. Announces Agreement to Acquire Peek Healthcare Technologies, Inc., to Support Over 2,500 Patients and $1.5MM Annual Revenue

  • TAMPA, FL / ACCESS Newswire / April 10, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced it has entered into a definitive agreement to acquire Peek Healthcare Technologies, Inc. ("Peek"). Peek operates the Peek Meds Marketplace, a digital prescription shopping platform built to empower consumers with real-time pricing transparency to assist consumers with making more informed medication purchase decisions.
  • 04/10/2025

Wellgistics Health Achieves SOC 2 Type 1 Compliance, Strengthening Security for AI-Driven Pharmacy Solutions and Employer-Based Healthcare Models

  • TAMPA, FL, March 18, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (“Wellgistics Health”), a provider of pharmacy solutions and healthcare technology, has successfully completed a third-party audit and achieved SOC 2 Type 1 compliance. This milestone validates that Wellgistics Health meets the industry's highest standards for security, availability, processing integrity, confidentiality, and privacy, reinforcing its commitment to data protection and regulatory compliance.
  • 03/18/2025

Wellgistics Health, Inc. Announces Leadership Transition: Brian Norton Appointed as CEO Following Tim Canning's Departure

  • TAMPA, FL, March 04, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX) (the “Company”), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that Tim Canning, Chief Executive Officer, will be departing the company. Mr. Canning's leadership tenure helped guide Wellgistics Health through pivotal phases, and the Company expresses gratitude for his contributions.
  • 03/04/2025

Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

  • ROXYBOND, formulated with patented, first-of-its-kind abuse-deterrent technology SentryBond ™ , is designed to provide multiple levels of protection
  • 03/04/2025

Wellgistics Expands Healthcare Ecosystem with Tollo Health Agreement, Targeting Multi-Billion Dollar GLP-1 and Long COVID Market

  • Tampa, Florida, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX, the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced that its wholly owned subsidiary, Wellgistics LLC, has entered into an agreement with Tollo Health, LLC (“Tollo”) to market Tollo's emerging proprietary suite of novel medical food products for GLP-1 treatment-related side effects, including muscle loss and Long COVID to pharmacies. Tollo is bringing to market novel, proprietary medical food products to address muscle loss and gut discomfort associated with GLP-1 drug use, and persistent viral infection(s), gut discomfort, sarcopenia, immune dysregulation, cellular senescence, endothelial damage and general nutritional support for patients with Long COVID. Tollo's first marketed product is Galectovid™, a proprietary medical food for the dietary management of Galectin-1 & 3 associated viral infections. Further details on Galectovid™ are available at www.galectovid.com .
  • 02/26/2025

Wellgistics Health, Inc. Announces Closing of $4.0 Million Initial Public Offering

  • Tampa, Florida, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (the "Company"), a holding company for various existing and planned strategic businesses centered around healthcare technology and pharmaceutical services, today announced the closing of its initial public offering (the "Offering") of 888,889 shares of its common stock at a public offering price of $4.50 per share. The shares have been approved for listing on the Nasdaq Capital Market and commenced trading on February 21, 2025, under the ticker symbol "WGRX."
  • 02/24/2025

U.S. IPO Weekly Recap: IPO Calendar Slows Down With Small Listings

  • The calendar slowed down this past week, with only small listings in the US. There was one sizable filing this past week - AIRO Group Holdings. No IPOs are currently scheduled to list in the week ahead, although some small deals may list throughout it.
  • 02/22/2025
Unlock
WGRX Ratings Summary
WGRX Quant Ranking